文献速递产科母胎医学

有早产风险妊娠中单疗程与两疗程产前皮质类固醇比较:MACS试验二次分析

One vs 2 courses of antenatal corticosteroids in pregnancies at risk of preterm birth: a secondary analysis of the MACS trial.
PubMed 文献 · Am J Obstet Gynecol MFM · 2023-05-04

本研究为MACS随机对照试验的二次分析,纳入仅接受1个疗程干预(第二疗程产前皮质类固醇或安慰剂)的孕妇,比较单疗程与第二疗程产前皮质类固醇对严重新生儿疾病和死亡的影响。结果显示第二疗程未改善复合主要结局(24% vs 20%,校正OR 1.09,95%CI 0.76-1.57),但小于胎龄儿风险升高(14.9% vs 10.6%,校正OR 1.63,95%CI 1.07-2.47)。

要点

  • 第二疗程产前皮质类固醇未降低复合主要结局(校正OR 1.09,95%CI 0.76-1.57)。
  • 暴露于产前皮质类固醇的新生儿小于胎龄儿风险更高(校正OR 1.63,95%CI 1.07-2.47)。
  • 亚组分析中<32周或干预后7天内出生者,第二疗程未见复合主要结局获益。

核心结论

  • 第二疗程产前皮质类固醇未改善新生儿死亡及严重疾病(包括严重呼吸窘迫综合征)。
  • 政策制定者在推荐第二疗程产前皮质类固醇时需审慎,并考虑能否获得短期及长期获益。

研究设计与样本

  • 本研究为多疗程产前皮质类固醇预防早产(MACS)试验的二次分析。
  • MACS试验为2001至2006年在20个国家80个中心开展的随机临床试验。
  • 纳入仅接受1个疗程干预(第二疗程产前皮质类固醇或安慰剂)的参与者,产前皮质类固醇组385例、安慰剂组365例。

主要发现

  • 复合主要结局在产前皮质类固醇组和安慰剂组的发生率分别为24%和20%(校正OR 1.09,95%CI 0.76-1.57)。
  • 严重呼吸窘迫综合征发生率两组相似(校正OR 0.98,95%CI 0.65-1.48)。
  • 产前皮质类固醇暴露的新生儿更可能为小于胎龄儿(14.9% vs 10.6%;校正OR 1.63,95%CI 1.07-2.47)。
  • 单胎妊娠中,复合主要结局(校正OR 1.29,95%CI 0.82-2.01)和出生体重<第10百分位(校正OR 1.74,95%CI 1.06-2.87)结果一致。
  • 亚组分析中,<32周出生者复合主要结局为50.5% vs 41.8%(校正OR 1.16,95%CI 0.78-1.72);干预后7天内出生者为42.3% vs 37.1%(校正OR 1.02,95%CI 0.67-1.57),均未见获益。

临床怎么用

  • 原文结论未据此给出具体临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Birth is unpredictable and many patients who receive antenatal corticosteroids for preterm birth remain pregnant. Some professional societies recommend rescue antenatal corticosteroids for those who remain pregnant ≥14 days following the initial course. OBJECTIVE: This study aimed to explore a single vs a second course of antenatal corticosteroids in terms of severe neonatal morbidity and mortality. STUDY DESIGN: This is a secondary analysis of the Multiple Courses of Antenatal Corticosteroids for Preterm Birth (MACS) trial. The MACS study was a randomized clinical trial conducted in 80 centers in 20 different countries from 2001 to 2006. Participants who received only 1 course of intervention (ie, either a second course of antenatal corticosteroids or placebo) were included in this study. The primary outcome was a composite of stillbirth, neonatal mortality in the first 28 days of life or before discharge, severe respiratory distress syndrome, bronchopulmonary dysplasia, intraventricular hemorrhage stage III and IV, periventricular leukomalacia, and necrotizing enterocolitis. Two subgroup analyses were planned to address the effect of a second course of antenatal corticosteroids on infants born before 32 weeks or within 7 days from the intervention. Moreover, a sensitivity analysis was performed to assess the effect of intervention on singleton pregnancies. Baseline characteristics were compared between the groups using chi-square and Student t tests. Multivariable regression analysis was performed to adjust for confounding variables. RESULTS: There were 385 and 365 participants included in the antenatal corticosteroid and placebo groups, respectively. The composite primary outcome occurred in 24% and 20% of participants in the antenatal corticosteroid and placebo groups, respectively (adjusted odds ratio, 1.09; 95% confidence interval, 0.76-1.57). Moreover, severe respiratory distress syndrome rate was similar between the 2 groups (adjusted odds ratio, 0.98; 95% confidence interval, 0.65-1.48). Newborns exposed to antenatal corticosteroids were more likely to be small for gestational age (14.9% vs 10.6%; adjusted odds ratio, 1.63; 95% confidence interval, 1.07-2.47). These findings remained true among singleton pregnancies for the primary composite outcome and birthweight <10th percentile (adjusted odds ratio, 1.29 [0.82-2.01]; and adjusted odds ratio, 1.74 [1.06-2.87]; respectively). Subgroup analyses of infants born before 32 weeks or within 7 days from the intervention did not show any benefits in terms of the composite primary outcome with antenatal corticosteroids vs placebo (50.5% vs 41.8% [adjusted odds ratio, 1.16; 95% confidence interval, 0.78-1.72]; and 42.3% vs 37.1% [adjusted odds ratio, 1.02; 95% confidence interval, 0.67-1.57]; respectively). CONCLUSION: Neonatal mortality and severe morbidities, including severe respiratory distress syndrome, were not improved by a second course of antenatal corticosteroids. Policy makers need to be thoughtful when recommending a second course of antenatal corticosteroids and consider whether not only short-term but also long-term benefits can be gained from such administration.

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. Baghlaf H, Snelgrove JW, Li Q, et al. One vs 2 courses of antenatal corticosteroids in pregnancies at risk of preterm birth: a secondary analysis of the MACS trial. Am J Obstet Gynecol MFM. 2023. PMID: 37149145. doi:10.1016/j.ajogmf.2023.101002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。